510 related articles for article (PubMed ID: 10535940)
21. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
[TBL] [Abstract][Full Text] [Related]
22. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
23. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
Pioli PA; Rigby WF
J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223
[TBL] [Abstract][Full Text] [Related]
24. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
Tsuchiya H; Iseda T; Hino O
Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032
[TBL] [Abstract][Full Text] [Related]
25. The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta.
Iturrioz X; Durgan J; Calleja V; Larijani B; Okuda H; Whelan R; Parker PJ
Biochem J; 2006 Jul; 397(1):109-20. PubMed ID: 16669786
[TBL] [Abstract][Full Text] [Related]
26. One ring to rule a superfamily of E3 ubiquitin ligases.
Tyers M; Willems AR
Science; 1999 Apr; 284(5414):601, 603-4. PubMed ID: 10328744
[No Abstract] [Full Text] [Related]
27. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases.
Mahrour N; Redwine WB; Florens L; Swanson SK; Martin-Brown S; Bradford WD; Staehling-Hampton K; Washburn MP; Conaway RC; Conaway JW
J Biol Chem; 2008 Mar; 283(12):8005-13. PubMed ID: 18187417
[TBL] [Abstract][Full Text] [Related]
29. The COP9/signalosome increases the efficiency of von Hippel-Lindau protein ubiquitin ligase-mediated hypoxia-inducible factor-alpha ubiquitination.
Miyauchi Y; Kato M; Tokunaga F; Iwai K
J Biol Chem; 2008 Jun; 283(24):16622-31. PubMed ID: 18424433
[TBL] [Abstract][Full Text] [Related]
30. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.
Lonergan KM; Iliopoulos O; Ohh M; Kamura T; Conaway RC; Conaway JW; Kaelin WG
Mol Cell Biol; 1998 Feb; 18(2):732-41. PubMed ID: 9447969
[TBL] [Abstract][Full Text] [Related]
31. Mammalian mediator subunit mMED8 is an Elongin BC-interacting protein that can assemble with Cul2 and Rbx1 to reconstitute a ubiquitin ligase.
Brower CS; Sato S; Tomomori-Sato C; Kamura T; Pause A; Stearman R; Klausner RD; Malik S; Lane WS; Sorokina I; Roeder RG; Conaway JW; Conaway RC
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10353-8. PubMed ID: 12149480
[TBL] [Abstract][Full Text] [Related]
32. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
33. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
[TBL] [Abstract][Full Text] [Related]
34. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex.
Melville MW; McClellan AJ; Meyer AS; Darveau A; Frydman J
Mol Cell Biol; 2003 May; 23(9):3141-51. PubMed ID: 12697815
[TBL] [Abstract][Full Text] [Related]
35. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
Ohh M; Takagi Y; Aso T; Stebbins CE; Pavletich NP; Zbar B; Conaway RC; Conaway JW; Kaelin WG
J Clin Invest; 1999 Dec; 104(11):1583-91. PubMed ID: 10587522
[TBL] [Abstract][Full Text] [Related]
36. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.
Hergovich A; Lisztwan J; Barry R; Ballschmieter P; Krek W
Nat Cell Biol; 2003 Jan; 5(1):64-70. PubMed ID: 12510195
[TBL] [Abstract][Full Text] [Related]
37. Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.
Takagi Y; Pause A; Conaway RC; Conaway JW
J Biol Chem; 1997 Oct; 272(43):27444-9. PubMed ID: 9341197
[TBL] [Abstract][Full Text] [Related]
38. The von Hippel-Lindau tumor suppressor protein.
Ivan M; Kaelin WG
Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
[TBL] [Abstract][Full Text] [Related]
39. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway.
Lisztwan J; Marti A; Sutterlüty H; Gstaiger M; Wirbelauer C; Krek W
EMBO J; 1998 Jan; 17(2):368-83. PubMed ID: 9430629
[TBL] [Abstract][Full Text] [Related]
40. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
Kamura T; Sato S; Iwai K; Czyzyk-Krzeska M; Conaway RC; Conaway JW
Proc Natl Acad Sci U S A; 2000 Sep; 97(19):10430-5. PubMed ID: 10973499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
